On November 10, according to Novo Nordisk China, Novo Nordisk announced that compensation for the drug patent term of its Novartite® patent related to chronic kidney disease indications has been approved by the State Intellectual Property Office, and the patent protection period for related indications has been extended by 5 years to March 2031.

Zhitongcaijing · 2d ago
On November 10, according to Novo Nordisk China, Novo Nordisk announced that compensation for the drug patent term of its Novartite® patent related to chronic kidney disease indications has been approved by the State Intellectual Property Office, and the patent protection period for related indications has been extended by 5 years to March 2031.